Trizepatide cas:2023788-19-2
tirzepatide is a once-weekly glucose-dependent insulin-stimulating polypeptide (GIP, aka: gastric inhibitory polypeptide) receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist developed by Lilly. Both GIP and GLP-1 are hormones secreted by the gut that promote insulin secretion. tirzepatide combines the effects of two insulin-promoting drugs into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.
tirzepatide is the first dual GIP/GLP-1 receptor agonist to complete a Phase 3 trial. In December 2020, Lilly announced that the Phase III monotherapy study SURPASS-1 surpassed both the primary and secondary endpoints: patients in the tirzepatide treatment group experienced significant reductions in hemoglobin A1C and body weight from baseline compared with placebo.
Hebei Weimiao Network Technology Co., Ltd. is a professional production and sales of chemical, cosmetic raw materials, plant extracts, cosmetics, pharmaceutical intermediates, metal materials manufacturers.
Founded in Hebei Province, the company has developed into a professional enterprise integrating
production, sales and technology development. At present, our products havebeen exported to Europe, the Middle East, Southeast Asia, the United States, Latin America, South America, Australia and other countries and regions. We will be your proud partner in China.
We will be a Chinese partner that make you proud , and we make efforts to provide you with professional and timely service.Look forward to establishing a good faith and friendly relationship with you.
China
